AstraZeneca shares fall to two month low following disappointing lung cancer trial results
Lung cancer drug results fall short of expectationsShares fall to two month lowPremium valuation to the sectorAstraZeneca (AZN) shares were bottom of the blue chip FTSE 100 on Monday, dropping 5.6% to £106.45 after disappointing...
03 July 2023
